Taysha Gene Therapies (NASDAQ:TSHA) Releases Earnings Results

Taysha Gene Therapies (NASDAQ:TSHA) released its quarterly earnings data on Monday. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01, Zacks reports. The business had revenue of $1.11 million for the quarter, compared to the consensus estimate of $3.62 million. Taysha Gene Therapies had a negative return on equity of 782.81% and a negative net margin of 833.60%. During the same quarter in the prior year, the business posted ($0.38) EPS.

Taysha Gene Therapies Stock Performance

TSHA stock traded up $0.24 during trading on Tuesday, reaching $2.28. The stock had a trading volume of 1,762,191 shares, compared to its average volume of 2,522,804. The stock’s 50 day moving average is $2.62 and its two-hundred day moving average is $2.55. The firm has a market cap of $426.41 million, a PE ratio of -4.65 and a beta of 0.41. Taysha Gene Therapies has a 52 week low of $1.27 and a 52 week high of $4.32. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.75.

Insider Activity

In related news, major shareholder Paul B. Manning purchased 1,333,333 shares of the business’s stock in a transaction on Thursday, June 27th. The stock was acquired at an average price of $2.25 per share, with a total value of $2,999,999.25. Following the completion of the acquisition, the insider now owns 1,333,333 shares of the company’s stock, valued at approximately $2,999,999.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Piper Sandler lowered their price target on Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating on the stock in a report on Monday, July 1st. BMO Capital Markets began coverage on Taysha Gene Therapies in a research report on Thursday, June 27th. They issued an “outperform” rating and a $5.00 price objective on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, June 20th. Finally, Needham & Company LLC reduced their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a report on Monday. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $6.50.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.